Glaucoma News

LAS VEGAS – Some glaucoma risk factors are not related to IOP, highlighting the need for new therapeutic options that address other aspects of the disease process, Jessica Steen, OD, FAAO, said at Vision Expo West.

MONTEREY, Calif. — Fewer adverse events overall were reported in eyes receiving Allergan’s Xen gel stent to treat glaucoma vs. eyes undergoing trabeculectomy at 12 months in the Gold Standard Pathway Study, according to a poster.

MONTEREY, Calif. — MicroPulse transscleral laser therapy delivered with a functionally and ergonomically revised probe resulted in a greater IOP-lowering effect while maintaining the safety profile of the original, according to a poster.

Legislation recently passed by the California Assembly and Senate would allow optometrists in the state to use therapeutic lasers, remove lesions and perform corneal crosslinking.

Social functioning and dependency were significantly worse in patients with primary open-angle glaucoma compared with patients with normal tension glaucoma, according to a study published in the Journal of Glaucoma.

Increasing age, higher IOP and shallower anterior chamber depth were linked with elevated risk for primary angle-closure disease, according to a study in Ophthalmology.

Corneal hysteresis measurements remained stable in patients with glaucoma during routine follow-up and after cataract surgery over a 6-month period, according to an analysis published in the Journal of Glaucoma.

Shared genetic etiology was observed between myopic refractive error and the risk for primary open-angle glaucoma, according to a study in JAMA Ophthalmology.

Iantrek announced it closed $23 million in Series B financing that will go toward initiating clinical trials of its MIGS devices, according to a press release.

One of the most common questions I get asked by my patients with glaucoma is, “Doc, what else can I do to help my disease and prevent blindness?”